Subgroup analysis from the Phase I/II TRINITI-1 trial suggests that the presence of ESR1 mutations is associated with a poorer prognosis in patients with advanced HR+/HER2- breast cancer treated with a combination of exemestane, ribociclib, and everolimus following progression on prior therapies 59. The gene discussed is ESR1; the disease is breast carcinoma.